<DOC>
	<DOCNO>NCT01303029</DOCNO>
	<brief_summary>The purpose study evaluate efficacy combination gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Ability understand willingness sign write informed consent 2 . Able , investigator 's opinion , fulfill procedure exploration study 3 . Age ≥ 18 year old 4 . ECOG 02 5 . Life expectancy ≥ 12 week 6 . Patients metastatic adenocarcinoma pancreas , follow 7th edition TNM classification 7 . Histologically cytologically confirm diagnosis adenocarcinoma pancreas 8 . Measurable disease follow RECIST criterion version 1.1 9 . No previous systemic treatment metastatic pancreatic cancer Adjuvant chemotherapy al least 6 month enrollment allow . Patients neoadjuvant chemotherapy must complete treatment least 4 week trial entry . Toxicities associate previous treatment must resolve enrollment . Progression disease ( metastatic disease ) must confirm adjuvant treatment 10 . Adequate bone marrow function determine : Hemoglobin : ≥ 9 g/dL . ( patient hemoglobin &lt; 9 g/dL could transfuse inclusion study ) Platelets : ≥ 100 x 109/L Absolute Neutrophil account ( ANC ) ≥ 1,5 x 109/L 11 . Adequate liver function , determine : Serum bilirubin ≤ 1,5 x LSN AST , ALT ≤ 2,5 x LSN patient without liver metastasis . In patient liver metastasis ≤ 5 x LSN Alkaline phosphatase ≤ 2,5 x LSN ≤ 5 x LSN patient liver metastasis . In patient bone metastasis ≤ 10 x LSN 12 . Adequate renal function , determine : Creatinine clearance use CockcroftGault formula ≥ 50.0 ml/min 13 . Women childbearing potential must negative serum urine pregnancy test perform within 7 day prior randomization . Postmenopausal woman define amenorrheic least 12 month . Also , men woman enrol study must use adequate birth control ( eg. , abstinence , intrauterine device , oral contraceptive double barrier method surgically sterile ) , start signing informed consent least 6 month completion treatment last dose , whichever occur first 14 . Patients must undergo major surgical procedure within 4 week prior study treatment . The surgical wound completely heal 1 . Local pancreatic cancer ( stage IAIIB ) locally advance cancer ( stage III ) , follow TNM 7th edition classification . Patients metastatic disease relapse initial diagnosis local advance disease could include study 2 . Pancreatic endocrine tumor ampulloma 3 . Evidence carcinomatosis meningitis brain metastasis . In case clinical suspicious brain metastasis mandatory perform brain TAC/MR 4 week prior de inclusion . 4 . Primary tumor develop 5 year previous inclusion , except situ cervix carcinoma skin basocellular cancer properly treat 5 . Cardiovascular disease clinically significant ( active ) : Noncontrolled arterial hypertension ( Systolic pressure &gt; 150 mg Hg and/or diastolic pressure &gt; 100 mm Hg repeat pressure measurement ) Cerebrovascular accident/ictus ( ≤ 6 week prior inclusion ) Myocardial infarction ( ≤ 6 month prior inclusion ) Unstable angina Congestive cardiac insufficiency ( grade II superior follow New York Heart Association ( NYHA ) Severe cardiac arrythmia require treatment 6 . Significant ophthalmologic anomaly 7 . Deficit DihydropyrimidineDehydrogenase ( DPD ) 8 . Unable take oral drug . Previous surgical process affect absorption make need intravenous feed parenteral nutrition lipid 9 . Pregnancy woman lactation period 10 . Antineoplastic treatment ( chemotherapy , hormonal treatment , radiotherapy , surgery , biological therapy tumor embolization ) 4 week prior inclusion 11 . Previous treatment capecitabine EGFR inhibitor 12 . Metabolic disease disease , investigator 's opinion , might interfere treatment study 13 . Known hypersensibility study drug ( gemcitabine , erlotinib , capecitabine ) 5fluorouracile fluoropyrimidines 14 . Current infection grade ≥ 2 ( CTCAE ) 15 . Known human immunodeficiency virus infection , chronic infection hepatitis B C virus , severe uncontrolled intercurrent infection severe uncontrolled concomitant diseases 16 . Medical , psychological , psychiatric sociological condition would interfere patient participation study assessment result 17 . Current 30 day previous study treatment investigational drug participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>erlotinib</keyword>
	<keyword>capecitabine</keyword>
</DOC>